AL-108

DRUG2 trials

Sponsors

Allon Therapeutics, University of California, Los Angeles

Conditions

Mild Cognitive Impairment, So StatedSchizophrenia

Phase 2

Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment

CompletedNCT00422981

Allon TherapeuticsMild Cognitive Impairment, So Stated

Start: 2007-01-31End: 2008-01-31Updated: 2012-10-24

A Multicenter Study of NAP (AL-108) in Schizophrenia

CompletedNCT00505765

University of California, Los AngelesSchizophrenia

Start: 2007-07-31End: 2009-04-30Updated: 2017-03-10

Related Papers

Davunetide sex-dependently boosts memory in prodromal Alzheimer's disease.

2024-10-0213 citations